共 50 条
- [31] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemiaINVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565Mori, MasamichiKaneko, NaokiUeno, YokoYamada, MasakiTanaka, RurikoSaito, RikaShimada, ItsuroMori, KenichiKuromitsu, Sadao
- [32] Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitorsBLOOD, 2020, 136Numan, YazanRahman, Zaid AbdelGrenet, JustinBoisclair, StephanieBewersdorf, Jan PhilippBarth, DylanZeidan, Amer M.Yilmaz, MusaDinner, ShiraDeutsch, Yehuda E.Frankfurt, OlgaLitzow, MarkAl-Kali, ArefForan, James M.Sproat, Lisa Z.Jovanovic, BorkoDaver, NavalPerl, Alexander E.Altman, Jessica K.
- [33] Novel treatments for relapsed/refractory acute myeloid leukemia with FLT3 mutationsEXPERT REVIEW OF HEMATOLOGY, 2019, 12 (08) : 621 - 640Tallis, EranBorthakur, Gautam
- [34] A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in ProgressBLOOD, 2024, 144Short, Nicholas J.Ravandi, FarhadDaver, NavalDinardo, Courtney D.Borthakur, GautamKadia, Tapan M.Yilmaz, MusaIssa, Ghayas C.Abramova, ReginaGarza, Araceli IsabellaKantarjian, Hagop M.Abbas, Hussein A.
- [35] DEEP MOLECULAR RESPONSE TO GILTERITINIB IMPROVES SURVIVAL IN FLT3 MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIAHAEMATOLOGICA, 2017, 102 : 6 - 6Jessica, A.Perl, A.Cortes, J.Smith, C.Litzow, M.Hill, J.Larson, R.Liu, C.Ritchie, E.Strickland, S.Wang, E.Neubauer, A.Martinelli, G.Bahceci, E.Levis, M.
- [36] Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemiaLEUKEMIA, 2024, 38 (11) : 2410 - 2418Wang, JianxiangJiang, BinLi, JianLiu, LigenDu, XinJiang, HaoHu, JiandaYuan, MengheSakatani, TaishiKadokura, TakeshiTakeuchi, MasatoKosako, MasanoriMa, XiaoGirshova, LarisaTan, JeromeBondarenko, SergeyLee, Lily Wong LeeKhuhapinant, ArchrobMartynova, ElenaHasabou, Nahla
- [37] The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemiaCANCER MEDICINE, 2021, 10 (03): : 797 - 805Altman, Jessica K.Perl, Alexander E.Hill, Jason E.Rosales, MattBahceci, ErkutLevis, Mark J.
- [38] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemiaBiomarker Research, 7Juanjuan ZhaoYongping SongDelong Liu
- [39] Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia CellsBIOMOLECULES & THERAPEUTICS, 2024, 32 (05) : 577 - 581Thai, Thi LamHan, Sun-Young
- [40] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenibBlood Cancer Journal, 12Alexander E. PerlNaoko HosonoPau MontesinosNikolai PodoltsevGiovanni MartinelliNicki PanoskaltsisChristian RecherCatherine C. SmithMark J. LevisStephen StricklandChristoph RölligMarco Groß-LangenhoffWen-Chien ChouJe-Hwan LeeHisayuki YokoyamaNahla HasabouQiaoyang LuRamon V. TiuJessica K. Altman